Table 5.
Efficacy of HRV against RVGE and severe RVGE based on modified intention-to-treat subjects.
| VE against | Case number |
Efficacy (%, 95%CI) | |
|---|---|---|---|
| HRV |
Placebo |
||
| Na = 2950 | Na = 2982 | ||
| RVGE caused by G1–G4, G8–G9 serotypes | 29 | 94 | 69.21 (53.31, 79.69) |
| First RV season | 14 | 53 | 73.52 (52.28, 85.31) |
| Second RV season | 15 | 41 | 63.57 (34.19, 79.84) |
| Severe RVGE caused by G1–G4, G8–G9 serotypes | 5 | 58 | 91.36 (78.45, 96.53) |
| First RV season | 4 | 27 | 85.12 (57.46, 94.79) |
| Second RV season | 1 | 31 | 96.77 (76.34, 99.56) |
| Hospitalization caused by G1–G4, G8–G9 serotypes | 3 | 28 | 89.21 (64.51, 96.72) |
| First RV season | 2 | 11 | 81.69 (17.39, 95.94) |
| Second RV season | 1 | 17 | 94.08 (55.49, 99.21) |
| RVGE caused by any serotype | 53 | 142 | 62.88 (49.11, 72.92) |
| First RV season | 23 | 73 | 68.47 (49.62, 80.27) |
| Second RV season | 30 | 69 | 56.91 (33.84, 71.93) |
| Severe RVGE caused by any serotype | 11 | 76 | 85.51 (72.74, 92.30) |
| First RV season | 7 | 34 | 79.32 (53.35, 90.83) |
| Second RV season | 4 | 42 | 90.49 (73.47, 96.59) |
| Hospitalization caused by any serotype | 6 | 37 | 83.68 (61.34, 93.11) |
| First RV season | 4 | 15 | 73.15 (19.09, 91.09) |
| Second RV season | 2 | 22 | 90.85 (61.11, 97.85) |
a
N = subject number received HRV or placebo. RV: rotavirus. VE: vaccine efficacy. RVGE: rotavirus gastroenteritis.